ACR 3.08% 6.3¢ acrux limited

"The reduction in revenue due to Zyprexa patent expirations is...

  1. 126 Posts.

    "The reduction in revenue due to Zyprexa patent expirations is expected to be partially offset by growth in key franchises including Cymbalta, Cialis®, Humalog®, Humulin® and Forteo®, as well as continued growth of newer products such as Effient®, Axiron® and Tradjenta®."

    this implies that Axiron will be a material contributor to group revenue growth.

    pretty awesome to be mentioned in the same sentence as blockbuster names like cymbalta and cialis!
 
watchlist Created with Sketch. Add ACR (ASX) to my watchlist
(20min delay)
Last
6.3¢
Change
-0.002(3.08%)
Mkt cap ! $18.31M
Open High Low Value Volume
6.6¢ 6.6¢ 6.3¢ $5.23K 80.08K

Buyers (Bids)

No. Vol. Price($)
2 249878 6.3¢
 

Sellers (Offers)

Price($) Vol. No.
6.5¢ 73455 1
View Market Depth
Last trade - 15.55pm 05/07/2024 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.